Clinically meaningful itch relief in AD-1652
≥4-POINT REDUCTION IN PEAK PRURITUS NRS AT WEEK 16
(secondary endpoint)1-3,a,b
aFull Analysis Set includes all subjects randomized.1
bIn the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders.1
cAt Day 1, subjects (baseline weight <30 kg) received 600 mg of DUPIXENT.1
dAt Day 1, subjects (baseline weight ≥30 kg) received 400 mg of DUPIXENT.1
Explore more Peak Pruritus NRS efficacy results
View adult data VIEW ADOLESCENT (12 TO 17 YEARS) DATA VIEW INFANT TO PRESCHOOLER (6 MONTHS TO 5 YEARS) DATA
Peak Pruritus NRS assesses the average itch intensity over the previous 24 hours4
It is a patient-reported measure that uses a 0- to 10-point scale, with which patients are asked:
“On a scale of 0 to 10, how would you rate your itch overall (on average) during the previous 24 hours?”
0 - NONE
1
2
3
4
5
6
7
8
9
10 - THE WORST
IMAGINABLE
A reduction of at least 4 points in Peak Pruritus NRS from baseline is a clinically meaningful change.1
READY TO
PRESCRIBE
DUPIXENT?